Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Trial Profile

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Ruxolitinib (Primary) ; Methylprednisolone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Biomira USA
  • Most Recent Events

    • 04 Dec 2018 Results (n=31) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results assessing baseline and changes in sBCMA levels during cycle 1 as a predictor of response (n=28) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 05 Jun 2018 Results (n=22) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top